Filing Details
- Accession Number:
- 0001179110-21-001001
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2021-02-01 17:04:07
- Reporting Period:
- 2020-12-29
- Accepted Time:
- 2021-02-01 17:04:07
- Original Submission Date:
- 2020-12-31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 815094 | Abiomed Inc | ABMD | Surgical & Medical Instruments & Apparatus (3841) | 042743260 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1372715 | J Andrew Greenfield | C/O Abiomed, Inc. 22 Cherry Hill Drive Danvers MA 01923 | Vp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 Par Value | Acquisiton | 2020-12-29 | 5,000 | $21.55 | 36,930 | No | 4 | M | Direct | |
| Common Stock, $.01 Par Value | Disposition | 2020-12-29 | 5,000 | $321.00 | 31,930 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2020-12-29 | 5,000 | $0.00 | 5,000 | $21.55 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2015-05-14 | 2024-05-14 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock, $.01 Par Value | 12,032 | Indirect | By Trust |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | $66.25 | 2016-05-13 | 2025-05-13 | 0 | 5,000 | Direct |
| Common Stock | Stock Option (right to buy) | $99.62 | 2017-05-24 | 2026-05-24 | 0 | 5,000 | Direct |
| Common Stock | Stock Option (right to buy) | $134.51 | 2018-05-15 | 2027-05-15 | 0 | 6,500 | Direct |
| Common Stock | Stock Option (right to buy) | $381.97 | 2019-05-16 | 2028-05-16 | 0 | 4,000 | Direct |
| Common Stock | Stock Option (right to buy) | $266.39 | 2020-05-30 | 2029-05-30 | 0 | 7,000 | Direct |
| Common Stock | Stock Option (right to buy | $223.90 | 2021-05-29 | 2030-05-29 | 0 | 4,896 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2025-05-13 | 0 | 5,000 | Direct |
| 2026-05-24 | 0 | 5,000 | Direct |
| 2027-05-15 | 0 | 6,500 | Direct |
| 2028-05-16 | 0 | 4,000 | Direct |
| 2029-05-30 | 0 | 7,000 | Direct |
| 2030-05-29 | 0 | 4,896 | Direct |
Footnotes
- Grant to reporting person of option to buy shares of Common Stock under ABIOMED, Inc. 2008 Stock Incentive Plan.
- These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- Exercise of stock options pursuant to reporting owners 10b5-1 plan.
- Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- This price represents the sale price of the transactions on the reported date at $321.0000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- The original Form 4, filed on December 31, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on December 29, 2020 as a total of 5,000 shares sold when in fact the 5,000 shares of the Issuer's common stock were options exercised. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects the accurate balances under Table II and no change in the number of shares reported as beneficially owned by the reporting person.
Billionaire Hedge Funds
